# Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

> **NCT04956692** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 531 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab SC
- **BIOLOGICAL:** Pembrolizumab IV
- **DRUG:** Paclitaxel
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04956692
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-05
- **Primary completion:** 2023-04-04
- **Final completion:** 2026-10-14
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956692, "Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04956692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*